The multi-faceted cross-talk between the insulin and angiotensin II signaling systems

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 2, 2006, Pages 98-107

  Velloso, Licio A ^a,b,c   Folli, Franco ^a,b,c   Perego, Lucia ^a,b,c   Saad, Mario J A ^a,b,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiac hypertrophy; Hypertension; Insulin resistance

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SERINE; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TYROSINE;

ANTIHYPERTENSIVE ACTIVITY; CELL FUNCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; EXTRACELLULAR SPACE; HEART HYPERTROPHY; HORMONAL REGULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRACELLULAR SPACE; METABOLIC REGULATION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TARGET ORGAN;

ANGIOTENSIN II; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; INSULIN; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33644982837     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.611     Document Type: Review

References (88)

1. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169.
2. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
3. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000; 11: 362-368.
4. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33: 283-303.
5. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53: 2735-2740.
6. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
7. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33: 417-429.
8. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999; 84: 3J-10J.
9. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
10. Malbon CC. Insulin signaling: putting the 'G-' in protein-protein interactions. Biochem J 2004; 380: e11-e12.
11. Muller G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signaling cascade. FEBS Lett 2002; 531: 81-87.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on. Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
13. Griendling KK, Lassegue B, Murphy TJ, Alexander RW. Angiotensin II receptor pharmacology. Adv Pharmacol 1994; 28: 269-306.
14. Shirai H, Takahashi K, Katada T, Inagami T. Mapping of G protein coupling sites of the angiotensin II type 1 receptor. Hypertension 1995; 25: 726-730.
15. Bernstein KE, Ali MS, Sayeski PP, Semeniuk D, Marrero MB. New insights into the cellular signaling of seven transmembrane receptors: the role of tyrosine phosphorylation. Lab Invest 1998; 78: 3-7.
16. Sadoshima J. Versatility of the angiotensin II type 1 receptor. Circ Res 1998; 82: 1352-1355.
17. Ishida M, Marrero MB, Schieffer B, Ishida T, Bernstein KE, Berk BC. Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res 1995; 77: 1053-1059.
18. Sadoshima J, Izumo S. The heterotrimeric G q protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. EMBO J 1996; 15: 775-787.
19. Eguchi S, Numaguchi K, Iwasaki H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998; 273: 8890-8896.
20. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 2000; 275: 15 926-15 932.
21. Venema RC, Venema VJ, Eaton DC, Marrero MB. Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1. J Biol Chem 1998; 273: 30 795-30 800.
22. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24 539-24 542.
23. 2 receptor: new insights into an old system. Regul Pept 2001; 99: 175-182.
24. 2 receptor comes of age. Hypertension 2005; 45: 840-844.
25. Huang XC, Richards EM, Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem 1996; 271: 15 635-15 641.
26. Zhu M, Gelband CH, Moore JM, Posner P, Sumners C. Angiotensin II type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid. J Neurosci 1998; 18: 679-686.
27. Saad MJ, Carvalho CR, Thirone AC, Velloso LA. Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J Biol Chem 1996; 271: 22 100-22 104.
28. Velloso LA, Carvalho CR, Rojas FA, Folli F, Saad MJ. Insulin signaling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. Cardiovasc Res 1998; 40: 96-102.
29. Araujo EP, De Souza CT, Gasparetti AL, et al. Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance, hyperinsulinemia, and increased adiposity. Endocrinology 2005; 146: 1428-1437.
30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
31. Sykiotis GP, Papavassiliou AG. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 2001; 15: 1864-1869.
32. 1 blockers in the treatment of hypertension and syndrome X. Can J Cardiol 2000; 16(Suppl E): 41E-44E.
33. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-2565.
34. Saad MJ, Velloso LA, Carvalho CR. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 1995; 310: 741-744.
35. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A 1996; 93: 12 490-12 495.
36. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169.
37. 1 receptor. Nature 1995; 375: 247-250.
38. Carvalheira JB, Calegari VC, Zecchin HG, et al. The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 2003; 144: 5604-5614.
39. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 1997; 46: 1950-1957.
40. Tanti JF, Gremeaux T, van Obberghen E, Le Marchand-Brustel Y. Serine/ threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994; 269: 6051-6057.
41. Mothe I, van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem 1996; 271: 11 222-11 227.
42. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004; 94: 1211-1218.
43. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987; 17: 448-454.
44. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of Angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-188.
45. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and Angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261.
46. Fukuda N, Satoh C, Hu WY, Nakayama M, Kishioka H, Kanmatsuse K. Endogenous Angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001; 19: 1651-1658.
47. Damas J, Garbacki N, Lefebvre PJ. The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 2004; 20: 288-297.
48. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the Angiotensin Type 2 Receptor (AT2R) reduces Adipose cell size and protects from diet-induced obesity and Insulin resistance. Diabetes 2005; 54: 991-999.
49. 2 receptor. Mol Endocrinol 2000; 14: 795-804.
50. Cui TX, Nakagami H, Nahmias C, et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol 2002; 16: 2113-2123.
51. Chiang SH, Baumann CA, Kanzaki M, et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 2001; 410: 944-948.
52. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998; 32: 459-466.
53. Leclerc PC, Auger-Messier M, Lanctot PM, Escher E, Leduc R, Guillemette G. A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for Angiotensin II plays an important role in receptor trafficking and signaling. Endocrinology 2002; 143: 4702-4710.
54. Wyse BD, Prior IA, Qian H, et al. Caveolin interacts with the Angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 2003; 278: 23 738-23 746.
55. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J 1996; 15: 3806-3812.
56. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 1996; 16: 6985-6992.
57. Haque SJ, Harbor P, Tabrizi M, Yi T, Williams BR. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 1998; 273: 33 893-33 896.
58. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999; 19: 2416-2424.
59. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-1805.
60. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998; 95: 10 626-10 631.
61. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813-2819.
62. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14: 2816-2826.
63. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917-921.
64. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
65. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
66. Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 1998; 95: 114-119.
67. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42 394-42 398.
68. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000; 275: 15 985-15 991.
69. Sadowski CL, Choi TS, Le M, Wheeler TT, Wang LH, Sadowski HB. Insulin Induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5*. J Biol Chem 2001; 276: 20 703-20 710.
70. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47 944-47 949.
71. Calegari VC, Bezerra RM, Torsoni MA, et al. Suppressor of cytokine signaling 3 is induced by Angiotensin II in heart and isolated cardiomyocytes, and participates in desensitization. Endocrinology 2003; 144: 4586-4596.
72. Torsoni MA, Carvalheira JB, Calegari VC, et al. Angiotensin II (AngII) induces the expression of suppressor of cytokine signaling (SOCS)-3 in rat hypothalamus - a mechanism for desensitization of AngII signaling. J Endocrinol 2004; 181: 117-128.
73. Calegari VC, Alves M, Picardi PK, et al. Suppressor of cytokine signaling-3 provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 2005; 146: 579-588.
74. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434-5446.
75. Giorgetti S, Pelicci PG, Pelicci G, Van Obberghen E. Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor. Eur J Biochem 1994; 223: 195-202.
76. Holt KH, Kasson BG, Pessin JE. Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase. Mol Cell Biol 1996; 16: 577-583.
77. Sarbassov DD, Peterson CA. Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signaling pathways during myogenic differentiation. Mol Endocrinol 1998; 12: 1870-1878.
78. Eguchi S, Iwasaki H, Ueno H, et al. Intracellular signaling of Angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 1999; 274: 36 843-36 851.
79. Werry TD, Sexton PM, Christopoulos A. "Ins and outs" of seven-transmembrane receptor signaling to ERK. Trends Endocrinol Metab 2005; 16: 26-33.
80. 1 angiotensin receptor in cardiac hypertrophy: Angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 2004; 15: 405-408.
81. Zou Y, Komuro I, Yamazaki T, et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in Angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 1996; 271: 33 592-33 597.
82. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545.
83. Zecchin HG, Bezerra RM, Carvalheira JB, et al. Insulin signaling pathways in aorta and muscle from two animal models of insulin resistance-obese middle-aged and spontaneously hypertensive rats. Diabetologia 2003; 46: 479-491.
84. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of Angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672.
85. Kudoh S, Komuro I, Mizuno T, et al. Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 1997; 80: 139-146.
86. 1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98: 2453-2460.
87. 1 receptor function in OK cells. Am J Physiol Renal Physiol 2005; 288: F1213-F1219.
88. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by Angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87: 746-752.